# Care Step Pathway – Hypophysitis (inflammation of the pituitary gland)

# **Nursing Assessment**

#### Look:

- Does the patient appear fatiqued?
- Does the patient look listless?
- Does the patient look ill?
- Does the patient look uncomfortable?

#### Listen:

- Does the patient report:
  - o Change in energy?
  - o Headache?
  - o Dizziness?
  - o Nausea/vomiting?
  - o Altered mental status?
  - o Visual disturbances?
  - o Fever?

### Recognize:

- Low evels of hormones produced by pituitary gland (ACTH, TSH, FSH, LH, GH, prolactin)
- Brain MRI with pituitary cuts: enhancement and swelling of the pituitary gland.
- DDX adrenal Insufficiency: low cortisol and high ACTH
- DDX primary hypothyroidism: low free T4 and high TSH

## **Grading Toxicity (Overall)**

### Grade 1 (Mild)

Asymptomatic or mild symptoms; clinical or diagnostic observation only (headache, fatigue)

### **Grade 2 (Moderate)**

Moderate symptoms; limiting ageappropriate instrumental ADLs (headache, fatigue)

## Grade 3 (Severe)

Severe or medically significant symptoms; limiting self-care ADL (sepsis, severe ataxia)

## **Grade 4 (Potentially Life-Threatening)**

Urgent intervention required (sepsis, severe ataxia)

**Grade 5 (Death)** 

## Management

## **Overall Strategy:**

- Ipilimumab to be withheld for any symptomatic hypophysitis and discontinued for symptomatic reactions persisting ≥6 weeks or for inability to reduce steroid dose to ≤7.5 mg prednisone or equivalent per day
- Nivolumab to be withheld for Grade 2/3 hypophysitis and discontinued for Grade 4 hypophysitis. Pembrolizumab to be withheld for Grade 2 hypophysitis and withheld or discontinued for Grade 3/4 hypophysitis
- 1 mg/kg methylprednisolone (or equivalent) IV to be given daily
  - o If given during acute phase, may reverse inflammatory process
- To be followed with prednisone 1-2 mg/kg daily with gradual tapering over at least 4 weeks
- Long-term supplementation of affected hormones is often required
  - Secondary hypothyroidism requiring levothyroxine replacement
  - o Secondary hypoadrenalism requiring replacement hydrocortisone
    - Typical dose: 20 mg qAM and 10 mg qPM
- Assess risk of opportunistic infection based on duration of steroid taper (and consider prophylaxis if needed)
- Collaborative management approach with endocrinology (particularly if permanent loss of organ function)

### **Nursing Implementation:**

- ACTH and thyroid panel should be checked at baseline and prior to each dose of ipilimumab
- Ensure that MRI is ordered with pituitary cuts or via pituitary protocol
- Anticipate treatment with corticosteroid and immunotherapy hold
- Review proper administration of steroid
  - Take with food
  - o Take in AM
- Educate patient regarding possibility of permanent loss of organ function (pituitary; possibly others if involved [thyroid, adrenal glands])
- Sick-day instructions, vaccinations, etc

#### \*Steroid taper instructions/calendar as a guide but not an absolute

- Taper should consider patient's current symptom profile
- Close follow-up in person or by phone, based on individual need & symptomatology
- Anti-acid therapy daily as gastric ulcer prevention while on steroids
- Review steroid medication side effects: mood changes (anger, reactive, hyperaware, euphoric, mania), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down & report them (taper may need to be adjusted)

#### Long-term high-dose steroids:

- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose M/W/F; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- Avoid alcohol/acetaminophen or other hepatoxins

#### **RED FLAGS:**

- Symptoms of adrenal insufficiency



ACTH = adrenocorticotropic hormone; ADLs = activities of daily living; DDX = differential diagnosis; FSH = follicle-stimulating hormone; GH = growth hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; TSH = thyroid stimulating hormone.